{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:16:01Z","timestamp":1782998161574,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Acute myeloid leukemia (AML) necessitates timely treatment, yet the impact of prolonged time to treatment (TTT) on clinical outcomes remains debated, especially its impact on achieving measurable residual disease (MRD) negativity, a powerful prognostic indicator in AML. Methods: This retrospective study analyzed 196 adult AML patients treated with intensive chemotherapy, evaluating the effect of TTT on outcome measures and quality of response. TTT was categorized arbitrarily into &lt;8, 8\u201314, and &gt;14 days. Results: Results showed a median TTT of 11 days. Median overall survival (OS) was 414 days, with no significant differences among TTT groups (p = 0.48). Complete remission rate was 75.5%, with significantly higher rates in patients treated within 14 days (p = 0.004 and p = 0.006 for 8\u201314 and &lt;8 days, respectively) compared to &gt;14 days. MRD was assessed in 140 patients, with 35% achieving negativity, and no significant differences observed among TTT groups. Conclusions: This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.<\/jats:p>","DOI":"10.3390\/cancers17122028","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:08:06Z","timestamp":1750219686000},"page":"2028","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5083","authenticated-orcid":false,"given":"Elisa","family":"Buzzatti","sequence":"first","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8944-0795","authenticated-orcid":false,"given":"Giovangiacinto","family":"Paterno","sequence":"additional","affiliation":[{"name":"UOSD Mieloproliferative, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-8121","authenticated-orcid":false,"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-7222","authenticated-orcid":false,"given":"Fabiana","family":"Esposito","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5019-0020","authenticated-orcid":false,"given":"Lucia","family":"Cardillo","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Taka","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3797-0741","authenticated-orcid":false,"given":"Lucrezia","family":"De Marchi","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zomparelli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleda","family":"Zaganjori","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Mallegni","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Meddi","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-5296","authenticated-orcid":false,"given":"Federico","family":"Moretti","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cerroni","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"},{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, 44114 OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-4988","authenticated-orcid":false,"given":"Luca","family":"Maurillo","sequence":"additional","affiliation":[{"name":"UOSD Mieloproliferative, Policlinico Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4320-9253","authenticated-orcid":false,"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"Hematology, Department of Biomedicine and Prevention, University Tor Vergata of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?","volume":"136","author":"Kramer","year":"2020","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1002\/cncr.34894","article-title":"Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia","volume":"129","author":"Franco","year":"2023","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/bloodadvances.2024013182","article-title":"Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial","volume":"8","author":"Venditti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2022-167837","article-title":"ALLG AMLM26 Phase 1B\/2 study investigating novel therapies to target early relapse and clonal evolution as pre-emptive therapy in AML (INTERCEPT): A multi-arm, precision-based, recursive, platform trial","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Meddi, E., Savi, A., Moretti, F., Mallegni, F., Palmieri, R., Paterno, G., Buzzatti, E., Del Principe, M.I., Buccisano, F., and Venditti, A. (2023). Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043062"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_11","first-page":"3503","article-title":"Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group","volume":"29","author":"Schlenk","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0043-1762921","article-title":"Molecular MRD Assessment in Acute Myeloid Leukemias","volume":"44","author":"Harankhedkar","year":"2023","journal-title":"J. Med. Paediatr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli","year":"2013","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2018-99-111123","article-title":"Prognostic Impact of Time from Diagnosis to Initial Chemotherapy for Acute Myeloid Leukemia","volume":"132","author":"Kamoda","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V114.22.1617.1617","article-title":"Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS)","volume":"114","author":"Kohrt","year":"2009","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V128.22.3982.3982","article-title":"Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study","volume":"128","author":"Datta","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18381","article-title":"Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database","volume":"199","author":"Alsouqi","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/bloodadvances.2020003806","article-title":"Impact of treatment delay in acute myeloid leukemia revisited","volume":"5","author":"Juliusson","year":"2021","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2019-124150","article-title":"The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia","volume":"134","author":"Nassereddine","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chea, M., Rigolot, L., Canali, A., and Vergez, F. (2024). Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042150"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tiong, I.S., and Loo, S. (2023). Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054790"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: A project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: Recommendations from an expert panel on behalf of European leukemia net","volume":"9(9)","author":"Venditti","year":"2025","journal-title":"Blood Adv."},{"key":"ref_27","first-page":"2469","article-title":"Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens","volume":"109","author":"Baden","year":"2024","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bernardi, M., Ferrara, F., Carrabba, M.G., Mastaglio, S., Lorentino, F., Vago, L., and Ciceri, F. (2022). MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.890871"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V124.21.1289.1289","article-title":"Time from Hospital Admission to Induction Chemotherapy Adversely Affects Outcomes in Patients with Acute Myeloid Leukemia","volume":"124","author":"Maymani","year":"2014","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/12\/2028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:53:58Z","timestamp":1760032438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/12\/2028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17122028"],"URL":"https:\/\/doi.org\/10.3390\/cancers17122028","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}